

Edging forward: How the UN's language on drugs has advanced since 1990 (Version 2)

Jamie Bridge (IDPC), Christopher Hallam (IDPC), Marie Nougier (IDPC), Miguel Herrero Cangas (IDPC), Martin Jelsma (TNI), Tom Blickman (TNI), David Bewley-Taylor (GDPO) & Daisy Bowderly (IDPC)

Introduction

Diplomatic processes at the United Nations (UN) are notoriously slow and difficult, perhaps increasingly so in a modern world of multi-polar geopolitics and tensions. This is certainly no different for the highly charged issue of international drug control. After the UN General Assembly Special Session (UNGASS) on the 'world drug problem'¹ in New York in April 2016² – many stakeholders had come away with mixed feelings at best.³ Despite acknowledgements of the progress made in certain areas of the debate, and the rich content of some of the country and civil society statements, the UNGASS failed to deliver the 'wide-ranging and open debate that considers all options' that had been called for by the UN Secretary-General at the time, Ban Ki-Moon.⁴

Three years later, member states met again – this

time in Vienna – at a Ministerial Segment aimed to evaluate progress made since the adoption of the 2009 'Political Declaration and Plan of Action on international cooperation towards an integrated and balanced strategy to counter the world drug problem',⁵ and to pave the way for the next decade of drug policy. The event resulted in a Ministerial Declaration that looked back at ongoing challenges, and proposed actions for the way forward.⁶

In order to help digest and contextualise the UNGASS Outcome Document and the 2019 Ministerial Declaration, it is useful to take a broader look at how the agreed UN language on drug control has evolved and developed over the last quarter of a century. To this end, this paper explores a selection of key themes by analysing the consensus-based language agreed by UN member states in:



Adoption of the Outcome Document at the 2016 UNGASS, New York

- The '1990 Political Declaration and Global Programme of Action on international cooperation against illicit production, supply, demand, trafficking and distribution of narcotic drugs and psychotropic substances' – agreed at the first UNGASS on the topic of 'drug abuse'.⁷
- The 1993 General Assembly resolution entitled 'Measures to strengthen international cooperation against the illicit production, sale, demand, traffic and distribution of narcotic drugs and psychotropic substances and related activities' – agreed at a high-level meeting of the General Assembly as a follow-up to the 1990 Political Declaration.⁸
- The 1998 Political Declaration – agreed at the 20th UNGASS on the 'world drug problem'⁹ – and the accompanying 'Declaration on the Guiding Principles on Demand Reduction'.¹⁰
- The '2003 Joint Ministerial Statement and further measures to implement the action plans emanating from the twentieth special session of the General Assembly' – agreed at the 46th UN Commission on Narcotic Drugs (CND) after a mid-term review of the 1998 Political Declaration.¹¹
- The '2009 Political Declaration and Plan of Action on international cooperation towards an integrated and balanced strategy to counter the world drug problem' – agreed at the high-level segment of the 52nd CND.¹²
- The '2014 Joint Ministerial Statement on the implementation by member states of the political declaration and plan of action on international cooperation towards an integrated and balanced strategy to counter the world drug problem' – agreed at the 57th CND after a mid-term review of the 2009 Political Declaration.¹³
- The 2016 Outcome Document (UN General Assembly Resolution S30/1) entitled 'Our joint commitment to effectively addressing and countering the world drug problem' – agreed at the 30th UNGASS last April.¹⁴
- The 2019 'Ministerial Declaration on strengthening actions at the national, regional and international levels to accelerate the implementation of joint commitments to address and counter the world drug problem'.¹⁵

For each UN document, the authors also con-


sulted the relevant *travaux préparatoires* and a variety of other background papers to understand the context behind any changes in agreed language over time.

Success or failure of drug control

Since 1990, the UN drug control system has set itself audacious goals to significantly reduce and even eradicate the global drug market, and has therefore faced a difficult dilemma – how to emphasise the ongoing priority of an escalating world drug problem, without openly acknowledging the inherent failure and ineffectiveness of existing policies and approaches.

In the 1990 Political Declaration, member states were 'Deeply alarmed by the magnitude of the rising trend in the illicit demand, production, supply, trafficking and distribution of narcotic drugs', and 'Deeply concerned about the violence and corruption' generated by illegal drug markets. Yet they failed to acknowledge any shortcoming of the international drug conventions, but rather re-stated the aspirations for 'an international society free of illicit drugs and drug abuse'. The 1993 General Assembly Resolution was also 'Profoundly alarmed by the magnitude of the rising trend in drug abuse', which 'should be accorded a higher priority by Governments, the United Nations and all other relevant national, regional and international organizations'. The document acknowledged that this dilemma 'requires the formulation of new strategies', but then proceeds to offer none – rather the operative paragraphs comprise language of 'reaffirming' and 'strengthening' while calling on member states to 'ratify and to implement fully all provisions' of the international drug control treaties.

The 1998 Political Declaration cites member



states' 'unwavering determination and commitment to overcoming the world drug problem', and proceeds to recognise 'with satisfaction the progress achieved by States, both individually and working in concert' – without elaborating on what this progress might be. Member states set '2008 as a target date for States, with a view to eliminating or reducing significantly the illicit manufacture, marketing and trafficking of psychotropic substances' (the 1998 UNGASS itself was held under the slogan 'A Drug Free World – We Can Do It!'¹⁶) – yet makes no allusion to a similar goal being set in 1990 with no success. In fact, 'the language was of re-affirmation; the words "evaluate", "examine", "scientific review", "identify weakness", "appropriate adjustments" or "develop new strategies" failed to... make it into the final resolution'.¹⁷

The target date of 2008 for a drug-free world saw member states engage in an evaluation process, informed by a break-through report from the Executive Director of the United Nations Office on Drugs and Crime (UNODC), entitled 'Making drug control fit for purpose: Building on the UNGASS decade'.¹⁸ This paper stated, 'The benefit of hindsight is the insight it offers us to evaluate the present and enrich future policy. Looking back over the last century, we can see that the control system and its application have had several unintended consequences – they may or may not have been unexpected, but they were certainly unintended'. These 'unintended consequences' included the creation of the criminal black market and the stigmatisation of people who use drugs.

Yet the following year's Political Declaration, drafted by member states through consensus rather than by senior UNODC officials, reverted to form. It opens with an acknowledgement that 'the drug problem continues to pose a serious threat to the health, safety and well-being of all humanity', 'the unprecedented surge in illicit opium production', 'growing violence' from drug trafficking, and 'increasing links between drug trafficking, corruption and other forms of organized crime'. Yet it merely extends the deadline for a drug-free world to 2019, by which time member states should 'eliminate or reduce significantly and measurably' drug cultivation, demand, production, diversion and drug-related money-laundering.

Refreshingly, however, each sub-section of the accompanying Plan of Action opens with a relatively frank 'Problem' section – noting, for example, that the 'commitments made by Member States in 1998 to attain significant and measurable results in the area of drug demand reduction have been attained only to a limited extent, owing largely to the lack of a balanced and comprehensive approach', and that 'efforts have not led to a significant overall decrease in the global illicit cultivation of crops used for the production of narcotic drugs'. The numerous 'Problem' assessments in this document also cite: 'insufficient emphasis on human rights and dignity'; the use of interventions 'not based entirely on scientific evidence'; 'inadequately trained personnel'; 'increasing levels of harm and violence'; the 'special problem' posed by synthetic drugs; 'Disparities... among States with respect to legislative provisions'; and that 'Countries not previously targeted by traffickers are now used as areas of diversion'.

The 2014 Joint Ministerial Statement states that '15 years after the commitments made at the twentieth special session of the General Assembly to address the world drug problem, notwithstanding the ever-increasing efforts and progress made by States, relevant international organizations and civil society, the drug problem continues to pose a serious threat to the health, safety and well-being of all humanity' (Paragraph 6). Tellingly, the document switches to language of containment and stability in spite of targets to eliminate and reduce: 'supply and demand of narcotic drugs... have remained largely stable during the past five years'. This mirrors a narrative in the UNODC World Drug Reports at the time – which for some 'should be seen as a purposive attempt to claim success and shore up the system',¹⁹ but for others does represent a positive shift away from 'drug-free world' rhetoric. For the first time, the 2014 Joint Ministerial Statement also specifically referenced and recommitted to a target from the 2011 UN Political Declaration on HIV to reduce the transmission of HIV among people who inject drugs by 50% by 2015.²⁰ This target was spectacularly missed – with HIV incidence actually increasing by a third over this same period²¹ – and was unsurprisingly not mentioned again in the 2016 Outcome Document a few years later.

The closest that the 2016 Outcome Document came to acknowledging the failure of the international community to achieve its own targets was in the third preambular paragraph: ‘We recognize that, while tangible progress has been achieved in some fields, the world drug problem continues to present challenges to the health, safety and wellbeing of all humanity, and we resolve to reinforce our national and international efforts and further increase international cooperation to face those challenges’. The reference to ‘tangible progress’ was contentious, and the original addition of ‘measurable’ was removed during the negotiations. Furthermore, while the submission from the United Nations Development Programme (UNDP) stated that there is ‘widespread recognition from several quarters, including UN member states and entities and civil society, of the collateral harms of current drug policies, and that new approaches are both urgent and necessary’,²² no such critique was included in the final document. Instead, and despite the target date being only three years ahead, the language of ‘elimination’ remained from the 2009 Political Declaration, and the 2016 Outcome Document also disappointingly reaffirmed ‘our determination to... actively promote a society free of drug abuse’ (although some stakeholders were keen to label this as an advance from previous language on a society free of drugs).

Following the lengthy negotiations during the 2016 Outcome Document, there was little appetite to begin this process again three years later. Therefore, the 2019 Ministerial Declaration reaffirms the commitments to the ‘aspirational goals’ made in the 2009, 2014 and 2016 documents, including commitments to ‘address and counter the world drug problem’ (paragraph 2), to ‘actively promote a society free of drug abuse’ (paragraph 4), and to ‘prevent, significantly reduce and work towards the elimination of illicit crop cultivation, and the production and manufacture of narcotic drugs and psychotropic substances’ (paragraph 11).

In its ‘Stocktaking’ section, the 2019 Ministerial Declaration sought to summarise the previous decade – and claims that ‘tangible process has been achieved in the implementation of the commitments made... in addressing and countering the world drug problem’ (paragraph 16) – although

there is little elaboration of what this ‘tangible’ progress actually is. Crucially, however, that short paragraph on progress is immediately followed by a far longer one noting ‘persistent and emerging challenges’. In many ways, this represents the most comprehensive acknowledgement of failures in a high-level UN document to date²³ – covering, among others, the expansion of drug markets and illicit trafficking, health services falling short of meeting needs, the unavailability of internationally controlled substances for medical and scientific purposes, increased deaths related to drug use, high transmission of HIV and hepatitis C, the rise in synthetic opioids (such as fentanyl), the lack of reliable data, and the recognition that drug policies ‘not in conformity with applicable international human rights obligations pose a challenge’ (paragraph 17). This long ‘stocktaking’ paragraph has since shaped the CND’s multi-year workplan of thematic intersessionals to discuss each challenge in more detail between 2019 and 2023.²⁴

Harm reduction

The bottom line for many advocates is that the UN drug control mechanism has failed to explicitly refer to harm reduction in any consensus-based document. Outside of Vienna, the UN General Assembly has adopted a series of political declarations on HIV/AIDS that explicitly refer to harm reduction,²⁵ with the 2011 Political Declaration also committing member states ‘to working towards reducing transmission of HIV among people who inject drugs by 50 per cent by 2015’.²⁶ The 2016 High Level Meeting on HIV/AIDS in New York similarly agreed a Political Declaration that notes ‘that some countries and regions have made significant progress in expanding health-related risk and harm reduction programmes’.²⁷ The words ‘harm reduction’ are also widely and now routinely used by UNODC,²⁸ the World Health Organization (WHO), UNAIDS and other UN agencies, and features prominently in the ‘UN System Common Position supporting the implementation of the international drug control policy through effective inter-agency collaboration’.²⁹ Yet it remains contentious at the CND in Vienna, with a small number of member states continuing to block its inclusion in drug policy documents³⁰ despite the

adoption of harm reduction in policy and/or practice by 100 countries and territories.³¹

The links between drug use and HIV/AIDS became increasingly recognised through the 1980s, and the 1990 Political Declaration stated that the WHO ‘shall be encouraged to continue to explore with Governments the development of health education programmes and policies for the reduction of risk and harm of drug abuse as a means of preventing the transmission by drug abusers of the human immunodeficiency virus (HIV)’ (Paragraph 35). Although the 1993 General Assembly Resolution contained no such references, an intergovernmental advisory group convened by the UN Drug Control Programme in the mid-1990s recommended ‘a more detailed study of the implications of decriminalisation and of harm reduction campaigns’ (which was dismissed by one participant as ‘the Trojan Horse of those factions championing the cause of legalisation’).³²

At the 1998 UNGASS, Greece,³³ the Netherlands,³⁴ Canada³⁵ and others presented and defended their domestic harm reduction programmes. Switzerland (represented by Ruth Dreifuss, the President at the time and now a member of the Global Commission on Drug Policy³⁶) spoke of their heroin, morphine and intravenous methadone prescription programmes and needle and syringe programmes.³⁷ New Zealand also made the following statement:

‘We are only now beginning to understand just how important this relatively simple and inexpensive [harm reduction] programme has been in terms of helping protect the public health of all New Zealanders. I note that there are those who vehemently oppose methadone or needle-exchange programmes. For me, the answer, “Well, it works”, seems to be the best response to these critics, who I suspect would have us blindly march down the road towards a “war on drugs”, a philosophy that many would consider has not worked’.³⁸

Although the 1998 Political Declaration was devoid of any strong harm reduction references, the accompanying Guiding Principles document was a clear step forward – citing that programmes ‘should reduce the adverse consequences of drug abuse for the individual and for society as a whole’ (Paragraph 5), and that demand reduction should aim at ‘reducing the adverse consequenc-

es of drug abuse’ (Paragraph 8b). Two years later, a UN Action Plan for the Implementation of the Declaration on the Guiding Principles of Drug Demand Reduction included as one of its specific outputs: ‘Easily accessible drug demand reduction programmes, integrated into broader health and social programmes, covering where possible the full spectrum of services, including reducing the adverse health and social consequences of drug abuse’.³⁹ In some ways, the harm reduction debate within the UN has continued to suffer from this classification as a sub-set of demand reduction rather than as a response in its own right – but this was the compromise that was needed at the time in order to secure progressive language on the need to tackle drug-related harms, and not just drug use itself.

The 2003 Joint Ministerial Statement acknowledged that ‘Many Governments have initiated special programmes targeting groups at risk, in particular drug-injecting abusers, in order to limit their exposure to infectious diseases’. It called for countries to further ‘develop and implement comprehensive demand reduction policies, including risk reduction activities, that are in line with sound medical practice and the international drug control treaties and that reduce the adverse health and social consequences of drug abuse’ and to provide ‘a comprehensive range of services for preventing the transmission of HIV/AIDS and other infectious diseases associated with drug abuse’. Yet two leaked documents at around this time demonstrated how political these discussions had become. A 2002 memo from UNODC’s legal experts to the International Narcotics Control Board (INCB) argued that most harm reduction measures are permissible under the international drug control conventions.⁴⁰ In 2004, a letter from the UNODC Executive Director to a senior US diplomat claimed that ‘Under the guise of harm reduction, there are people working disingenuously to alter the world’s opposition to drugs... this we cannot allow’⁴¹ (the USA was UNODC’s biggest donor and was staunchly opposed to harm reduction at the time).

Nonetheless, the harm reduction movement continued to grow in size and acceptance around the world, and the 2009 Political Declaration noted ‘with great concern the alarming rise in the incidence of HIV/AIDS and other blood-borne dis-

eases among injecting drug users', committed to 'work towards the goal of universal access to comprehensive prevention programmes and treatment, care and related support services', and cited the ground-breaking new WHO, UNODC, UNAIDS Technical Guide which explicitly outlined an evidence-based harm reduction package for the first time.⁴² During the negotiations, there were strong calls for references to harm reduction, but no text was approved unless there was complete consensus – which led to the diplomatic and heavily watered down compromise of 'related support services' throughout the document. Amidst tense negotiations, the Chair even called a straw poll at which 13 countries voted against a footnote on harm reduction, compared to 12 in favour.⁴³ This prompted Germany to submit an interpretive statement once the 2009 Political Declaration had been formally adopted. On behalf of 25 other countries,⁴⁴ they declared their interpretation of 'related support services' to mean harm reduction.⁴⁵ Interestingly, the 2009 Political Declaration also recommends 'a comprehensive treatment system' with 'opioid agonist and antagonist maintenance' – which includes key opioid agonist therapy (OAT) medicines such as methadone and buprenorphine.

These same debates continued during the nine-month negotiations of the 2014 Joint Ministerial Statement – similarly ending with the term harm reduction being omitted due to a lack of consensus despite strong support from some member states. Again, a verbose compromise was forged: 'measures aimed at minimizing the public health and social consequences of drug abuse, in accordance with national legislation and the three international drug control conventions'.⁴⁶ Crucially, the document notes that 'those States that have implemented the interventions outlined in the WHO, UNODC, UNAIDS Technical Guide... have remarkably reduced the number of HIV infections, with some countries approaching the elimination of injecting drug use-related transmission of HIV' – reflecting the discussions captured in the official CND report.⁴⁷

This brings us to the 2016 UNGASS when some member states and other participants attempted again to overcome the ideological impasse around the words 'harm reduction'. At the Special Session, 46 countries spoke in favour of harm reduc-

tion (including a coordinated statement from the 28 European Union (EU) member states), while just China and Singapore explicitly spoke against it.⁴⁸ Progressive harm reduction language had been proposed by member states, civil society and UN agencies⁴⁹ – including in the submissions from the WHO, the Office of the United Nations High Commissioner for Human Rights (OHCHR), UNDP, UNODC and UNAIDS (which called for the UNGASS to 'commit to fully implement harm reduction and HIV services', including in prisons).⁵⁰ Yet the term was once again omitted and replaced in Paragraph 1o, which eventually read:

'Invite relevant national authorities to consider, in accordance with their national legislation and the three international drug control conventions, including in national prevention, treatment, care, recovery, rehabilitation and social reintegration measures and programmes, in the context of comprehensive and balanced drug demand reduction efforts, effective measures aimed at minimizing the adverse public health and social consequences of drug abuse, including appropriate medication-assisted therapy programmes, injecting equipment programmes, as well as antiretroviral therapy and other relevant interventions that prevent the transmission of HIV, viral hepatitis and other blood-borne diseases associated with drug use, as well as consider ensuring access to such interventions, including in treatment and outreach services, prisons and other custodial settings, and promoting in that regard the use, as appropriate, of the technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, issued by the World Health Organization, the United Nations Office on Drugs and Crime and the Joint United Nations Programme on HIV/AIDS'

This was clear progress compared to previous language from 1998 and 2009, but at great expense in terms of diplomatic energy and resources – and is arguably no better and less clear than the 1990 Political Declaration language of 'health education programmes and policies for the reduction of risk and harm of drug abuse'. Nonetheless, supportive government delegations emerged feeling a small sense of victory after se-

curing the first explicit references to naloxone for reducing drug-related deaths (Paragraph 1j) and ‘injecting equipment programmes’ (Paragraph 1l). There was also a reference to ‘medication-assisted therapy’ in the same paragraph – which includes essential OST medicines such as methadone and buprenorphine, but can also include opiate antagonists and other medicines used in detoxification programmes (such as naltrexone).

Despite ongoing civil society advocacy, the term ‘harm reduction’ once again failed to make it into the 2019 Ministerial Declaration, which reverted to ‘measures aimed at minimizing the adverse public health and social consequences of drug abuse’ (paragraph 11) as member states sought to avoid the same difficult negotiations from three years before.

Human rights

In 2008, the then UN Special Rapporteur on the right to health, Paul Hunt, described the international drug control and human rights systems as ‘parallel universes’⁵¹ – and, until recently, this was reflected in the high-level UN documents on drug control. For example, the 1990 Political Declaration makes limited reference to the issue of human rights – with any mention relating more to the ‘grave and persistent threat’ of illegal drug markets rather than the dignity and rights of the millions of people involved in the drug trade. Direct references to important UN human rights documents and obligations, such as the UN Charter, are only made regarding the principles of international law, particularly ‘respect for the sovereignty and territorial integrity of states’.

Despite frequent discussion of the human rights implications of drug policy within the 1998 UN-GASS plenary discussions – particularly from representatives of Finland,⁵² Uruguay⁵³ and Denmark⁵⁴ – the 1998 Political Declaration adopts a similar, if slightly more progressive, stance to its predecessor. Reference is made to the UN Charter again in relation to state sovereignty and associated state rights. However, within the context of ‘shared responsibility’ and a ‘balanced approach’, states also commit themselves to respect ‘all human rights and fundamental freedoms’. On the 50th anniversary year of the UN Declaration of Human Rights, human rights concepts were still

being contested and simplified in relation to drug control – as demonstrated by the plenary comments of the Executive Director of the United Nations Drug Control Programme: ‘we should not forget that the notion that drug use is a kind of human right is inherently immoral, as it suggests that human lives are not worth saving from the devastation of addiction’.⁵⁵

The 2003 Joint Ministerial Statement did not include reference to human rights per se, but it did broaden the frame of reference by noting that, within the context of an integrated and balanced approach, action against the ‘world drug problem’ should be taken in ‘full conformity with the purposes and principles of the Charter of the United Nations and international law’ (Paragraph 2).

In 2008, however, Uruguay led on the first ever CND resolution focused on human rights with Resolution 51/12 on ‘Strengthening cooperation between the United Nations Office on Drugs and Crime and other United Nations entities for the promotion of human rights in the implementation of the international drug control treaties’.⁵⁶ The Uruguay delegation fought hard for this resolution to go through, marking the 60th anniversary of the Universal Declaration of Human Rights, and supported to varying degrees by Argentina, Belgium, Bolivia, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Peru, Romania, Slovenia (on behalf of the EU), Spain, Switzerland and the UK.⁵⁷ Yet it clearly ‘touched a nerve’ among other delegations: China stated that ‘Discussion of political issues such as human rights are inappropriate at CND’ and ‘It is ridiculous to require [the CND] to work in accordance with human rights law’, while Thailand was concerned that discussing human rights at the CND ‘will disrupt the tradition of consensus’.⁵⁸ The final language was watered down during negotiations, with references to the death penalty and the UN Declaration on the Rights of Indigenous Peoples being removed, among others⁵⁹ – yet it still represented a major step forward for the human rights debate in Vienna.

The 2008 Resolution was also an important precursor for the following year’s Political Declaration, which was clearly influenced by the increased levels of discussion around the intersection between human rights, wider state ob-

ligations and drug policy. Establishing itself as a 'fresh impetus to international drug control 10 years after 1998', the 2009 Political Declaration explicitly notes the importance of conducting drug policy in conformity with the UN Charter, international law and the Universal Declaration of Human Rights. Further, although state sovereignty remains an important concern, it is now bound up with concerns for 'the inherent dignity of all individuals'. Beyond this high-level comment, it is noteworthy that human rights also receive attention within Paragraph 24a on 'sustainable crop control strategies' (albeit again linked with states' rights) – as well as at numerous points within the accompanying 2009 Plan of Action.

By 2014, the connection between drug control and international law had become even more explicit. Indeed, in addition to broad statements concerning the UN Charter and the Universal Declaration of Human Rights, and building on the previous emphasis on individual rights, it is noted in the 2014 Joint Ministerial Statement that drug control efforts 'should continue to be addressed in a comprehensive, integrated and balanced manner, in full conformity with the three international drug control conventions and fully consistent with applicable international human rights obligations, on both the drug demand and supply reduction sides' (Paragraph 23). The 2014 Statement also notes several times the importance of human rights obligations at an operational level (such as Paragraphs 30 and 45). Again, however, it is clear from accompanying discussions within the CND that connotations of 'human rights' remained contested, especially in relation to use of the death penalty for drug-related offences.⁶⁰

Unable to secure an explicit reference to the abolition of the death penalty in 2014, this became a clear point of division and a pinch point for the consensus between member states in Vienna.⁶¹ After the Joint Ministerial Statement was approved, Greece (which held the Presidency of the EU at the time) made a statement on behalf of 57 other governments⁶² and 'deeply regretted that the Joint Ministerial Statement did not include language on the death penalty' while reiterating their 'strong and unequivocal opposition to the death penalty, in all circumstances'.⁶³ In retaliation, Iran's statement on behalf of 16 other countries⁶⁴ stated that every country has the sovereign

right to decide on its own justice system.

Inevitably, the death penalty also became a significant point of contention at the 2016 UNGASS, where 66 member states spoke out against its use, while 16 countries defended their right to apply this sanction for drug offences.⁶⁵ Ultimately, however, the Outcome Document failed again to include any mention – let alone condemnation – of the death penalty, despite lengthy and fraught CND negotiations throughout 2015 and 2016.⁶⁶ Again, the adoption of the document was immediately followed by a series of statements lamenting the issues on which there was no consensus.⁶⁷ Switzerland, Brazil, Costa Rica, Norway, Uruguay and the EU all spoke against the death penalty (the latter in a statement on behalf of 56 countries⁶⁸), while Indonesia read a counter-statement on behalf of 14 other countries.⁶⁹

Aside from the death penalty, however, the 2016 Outcome Document does contain strong and explicit references to human rights at several points, from high-order commitments to operational recommendations – including an entire thematic chapter specifically incorporating human rights. Linked to this, the Human Rights Council had passed its first ever resolution on drugs and human rights in 2015⁷⁰ calling for OHCHR to submit a report⁷¹ as part of the UNGASS preparations, and also held its first high-level panel on drug control in September 2015. Human rights commitments in the Outcome Document cover areas as wide as the rights of women and children, the right to health, and a human rights-based criminal justice approach. Paragraph 4l in particular has been lauded as an important 'win' with the strongest ever human rights provision within a UN drug control resolution – and does not include any of the usual caveats that diluted many of the other paragraphs of the Outcome Document:⁷²

'Promote and implement effective criminal justice responses to drug-related crimes to bring perpetrators to justice that ensure legal guarantees and due process safeguards pertaining to criminal justice proceedings, including practical measures to uphold the prohibition of arbitrary arrest and detention and of torture and other cruel, inhuman or degrading treatment or punishment and to eliminate impunity, in accordance with rel-

evant and applicable international law and taking into account United Nations standards and norms on crime prevention and criminal justice, and ensure timely access to legal aid and the right to a fair trial’

Much less progress was achieved in terms of indigenous rights in drug policy, in keeping with the 2007 UN Declaration on the Rights of Indigenous Peoples.⁷³ An attempt by Jamaica in 2016 to insert language on this issue received little support,⁷⁴ and the UN High Commissioner for Human Rights expressed strong disappointment about the Outcome Document: ‘it would have been better if it would be clearly indicated that indigenous peoples should be allowed to use drugs in their traditional or religious practices where there is historical basis for this’.⁷⁵ The root of this problem is the 1961 Single Convention on Narcotic Drugs, which specifically obliges member states to abolish all traditional uses – even though the subsequent 1971 Conventions acknowledges traditional and religious uses of plants containing psychotropic substances. As for the 1988 Convention (which is quoted in this regard in the 2016 Outcome Document), it mentions that eradication measures ‘shall respect fundamental human rights and shall take due account of traditional licit uses, where there is historic evidence of such use’, yet also states that those measures ‘shall not be less stringent’ than the provisions of the 1961 Convention.⁷⁶ In this sense, the Outcome Document contains an inherent contradiction – calling on member states to ‘respect fundamental human rights and take due account of traditional licit uses’, in accordance with the 1961 obligation to abolish them. With regards to indigenous rights, there is therefore an undeniable conflict between international human rights obligations and the UN drug control treaties (perhaps best exemplified by Bolivia’s decision to withdraw from the 1961 Convention in 2012, and then re-accede in 2013 with an exception for coca⁷⁷) – and the General Assembly has failed to correct this.

In 2019, the Ministerial Declaration affirmed member states’ ‘commitment to respecting, protecting and promoting all human rights, fundamental freedoms and the inherent dignity of all individuals and the rule of law in the development and implementation of drug policies’ (paragraph 5). It also, importantly, clearly ac-

knowledged that policies ‘not in conformity with applicable international human rights obligations pose a challenge to the implementation of joint commitments based on the principle of common and shared responsibility’ (paragraph 17).

This progress may be explained by the stronger acknowledgement of the human rights abuses committed in the name of drug control since 2016, including in various Human Rights Council resolutions on various aspects of drug policy (including on arbitrary detention, the death penalty and the Philippines).⁷⁸ Human Rights mechanisms have also highlighted issues associated with drug policy relevant to their own mandates,⁷⁹ and have become more regular CND participants, while the OHCHR published a second report, focusing on UNGASS implementation as it relates to drug control, in 2018.⁸⁰

In addition, in November 2018, the UN System Chief Executives Board for Coordination (CEB) adopted and released a common position on drug policy, that aimed ‘To support the development and implementation of policies that put people, health and human rights at the centre’.⁸¹ This groundbreaking common position called for policies that ‘address impunity for serious human rights violations in the context of drug control efforts’, and even for ‘changes in laws, policies and practices that threaten the health and human rights of people’. Disappointingly, however, the 2019 Ministerial Declaration failed to mention human rights in its section on the ‘Way forward’.

Overall, there has been progress in the human rights language, understanding and commitments in the UN drug control system, though the intersection between drug policy and human rights very much remains contested territory, with different states adopting very different perspectives. Additionally, there continues to be a disconnect between general statements made by member states concerning human rights and drugs, and specific obligations being incorporated in the successive high-level documents on global drug policy. This may be an inevitable result of multilateral negotiations and diplomacy in both Vienna and New York, but it remains a grey area in terms of member states’ obligations to ensure the protection of human rights in the framework of drug control.

Development

The first UN-supported crop substitution attempts can be traced back to the early 1970s, when development projects were initiated to reduce opium poppy cultivation in Thailand and cannabis cultivation in Lebanon.⁸² International recognition of a link between drugs and development was subsequently laid down in the 1988 Convention – which on the one hand obliges Parties to eradicate opium poppy, coca bush and cannabis plants, but also promotes international cooperation in support of ‘integrated rural development leading to economically viable alternatives to illicit cultivation’.⁸³ The 1988 Convention also highlighted that ‘factors such as access to markets, the availability of resources and prevailing socioeconomic conditions should be taken into account before such rural development programmes are implemented’.⁸⁴

The 1990 Political Declaration recognised ‘the links between the illicit demand, consumption, production, supply, trafficking and distribution of narcotic drugs and psychoactive substances and the economic, social and cultural conditions in the countries affected by them’, and underscored the need to increase development cooperation, and to ‘facilitate trade flows in support of viable alternative income schemes’. The lack of access to international markets was brought to the attention of the UNGASS by Colombian President Virgilio Barco, following the 1989 collapse of the International Coffee Agreement which prompted many bankrupted small Colombian coffee farmers to shift to illegal cultivation: ‘We cannot afford to talk idealistically of crop substitution in the case of the coca leaf while sabotaging Colombian farmers’ main cash crop [coffee] and the country’s largest export’, he told the General Assembly, adding that alternative development projects were welcome, ‘but even more important is the adoption of commercial and trade measures which allow our economy greater access to markets in the industrialized countries and fair prices for our exports’.⁸⁵ A 1993 General Assembly resolution further called on the international community to consider ‘ways to strengthen and enhance international anti-drug cooperation in programmes of alternative development in order to eliminate illicit drug production and trafficking

within the framework of sustainable development, with a view to improving living conditions and contributing to the eradication of extreme poverty’.⁸⁶

Yet it was at the 1998 UNGASS that alternative development became fully recognised as an important component of global drug policy. The Political Declaration was accompanied by an ‘Action Plan on International Cooperation on the Eradication of Illicit Drug Crops and on Alternative Development’, which stated the intention ‘to promote lawful and sustainable socio-economic options for those communities and population groups that have resorted to illicit cultivation as their only viable means of obtaining a livelihood, contributing in an integrated way to the eradication of poverty’.⁸⁷ The Action Plan also included cautionary wording about the proper sequencing of development interventions and eradication measures: ‘In cases of low-income production structures among peasants, alternative development is more sustainable and socially and economically more appropriate than forced eradication... the application of forced eradication might endanger the success of alternative development programmes’. Nonetheless, the Political Declaration itself also emphasized ‘the need for eradication programmes and law enforcement measures to counter illicit cultivation’ (Paragraph 18), and established 2008 as the deadline for ‘eliminating or reducing significantly the illicit cultivation of the coca bush, the cannabis plant and the opium poppy’.

At the 45th session of the CND in 2002, Resolution 45/14 commissioned ‘a rigorous and comprehensive thematic evaluation... for determining best practices... by assessing the impact of alternative development’.⁸⁸ The resulting report – ‘Alternative development: A global thematic evaluation’ – concluded that ‘The elimination of illicit crops should be conditional on improvements in the lives and livelihoods of households. It should not be a prerequisite for development assistance. Illicit crops should be eradicated only when viable alternatives exist for households participating in alternative development. Successful alternative development requires proper sequencing’.⁸⁹

In the negotiations for the 2009 Political Declaration, no consensus could be reached on the issue of conditionality, but on the sequencing is-

sue – after long debates – the following important clause was agreed: ‘Ensure, when considering taking eradication measures, that small-farmer households have adopted viable and sustainable livelihoods so that the measures may be properly sequenced in a sustainable fashion and appropriately coordinated’ (Paragraph 47g). Unfortunately, the 2013 ‘UN Guiding principles on alternative development’ slightly weakened that language by replacing ‘have adopted’ by ‘have opportunities’, but did include references to human development indicators and the Millennium Development Goals.⁹⁰ The Guidelines also called for efforts ‘to build and maintain confidence, dialogue and cooperation with and between stakeholders, from people at the community level and local authorities to leaders at the national and regional levels’, so as to ensure ‘local ownership and participation of the involved parties in the design, implementation, monitoring and evaluation of alternative development programmes and projects’.⁹¹

In 2016, the Outcome Document further strengthened this language, and was the first UN drug policy declaration to tackle the drugs and development issue in a section of its own, separated from eradication and law enforcement.⁹² It refers to ‘ensuring the empowerment, ownership and responsibility of affected local communities, including farmers and their cooperatives’, and also mentions cooperation with the UNODC, UNDP, the Food and Agriculture Organization (FAO), the International Labour Organization (ILO) and other relevant organisations ‘with a view to contributing to the building of peaceful, inclusive and just societies, consistent with the Sustainable Development Goals’ (Paragraph 7b). The 2016 Outcome Document also includes sub-sections on socioeconomic issues and development-oriented drug policies, and recommends targeting illegal cultivation ‘by implementing comprehensive strategies aimed at alleviating poverty and strengthening the rule of law... and by promoting sustainable development aimed at enhancing the welfare of the affected and vulnerable population through licit alternatives’ (Paragraph 7a). However, one paragraph in the development chapter still locks alternative development together with eradication and law enforcement, by calling for ‘strengthening sustainable crop control strategies that may include, inter alia, alternative

development, eradication and law enforcement measures, for the purpose of preventing and reducing significantly and measurably the illicit cultivation of crops’ (Paragraph 7c), while omitting any cautionary reference to proper sequencing or avoiding drug control conditionality. Finally, and perhaps most innovatively, the 2016 Outcome Document extends the scope of alternative development to the urban environment, encouraging ‘the development of sustainable urban development initiatives for those affected by illicit drug-related activities’ (Paragraph 7k).

The notion that sustainable development-oriented drug policies should apply to both rural and urban areas, and that they should be ‘adequately-sequenced, well-funded and long-term’, ‘bearing in mind environmental protection and sustainability’, was inscribed in the UN System Common Position on drugs. However, these critical elements failed to make it in the 2019 Ministerial Declaration a few months later. The 2019 document, in fact, made no further gains on development language, apart from the reiteration that ‘efforts to achieve the Sustainable Development Goals and to effectively address the world drug problem are complementary and mutually reinforcing’.

Civil society engagement

UN language around civil society involvement has been slowly evolving over time, growing in strength and breadth but at the same time becoming increasingly caveated in order to maintain consensus. This is no doubt a reflection of civil society participation in UN events on drugs – which, although much improved in the past few years, remains severely limited as compared to other UN forums such as the the UN Commission on Sustainable Development, the UN Environment Programme (UNEP), UNAIDS and the Human Rights Council.⁹³

The 1990 Political Declaration includes just one mention of the participation of non-governmental organisations (NGOs), in Paragraph 12 which focuses exclusively on their role in drug prevention and education. Three years later, the 1993 General Assembly resolution expanded NGO involvement beyond demand reduction by incorporating

language on the ‘Promotion and encouragement of the active involvement of non-governmental organizations and the private sector in the various aspects of the drug problem’ (Paragraph 10j). However, both the 1990 and 1993 documents make it clear that this engagement should aim at eliminating the illegal drug market.

This objective was even more prominent in the 1998 Political Declaration, in which the only paragraph mentioning civil society called upon ‘non-governmental organizations and the media worldwide actively to promote a society free of drug abuse’ (Paragraph 12). At the time, only a few NGOs actively participated in the 1998 UNGASS, but several member states – including the Presidents of Portugal and Costa Rica – already started to highlight the positive role played by civil society in implementing programmes on the ground. In his opening remarks, Hennadiy Udoenko (then President of the General Assembly) also stated that ‘Forging a new partnership with nongovernmental organizations, the private sector, labour unions, local communities and individual families is a prerequisite of long-term success’.⁹⁴

Meanwhile, a modern and more coordinated civil society movement in support of drug policy reform emerged after the frustrations and experiences of the 1998 UNGASS – calling for an overhaul of the outdated drug control regime, while also advocating for step-by-step pragmatic reforms of the most problematic aspects of the regime. This included closer collaboration with a blossoming harm reduction movement, which had generally been ignoring (and been ignored by) the Vienna-based UN discussions up to this point. Over the years, this resulted in the emergence of a core group of civil society organisations committed to being closely engaged in the UN debates – including the 2003, 2009, 2014 and 2016 meetings – and, in 2006, fed into the formation of the International Drug Policy Consortium (IDPC) itself.⁹⁵

A noteworthy step forward was achieved in the 2003 Joint Ministerial Statement, when the ‘close cooperation’ between civil society and governments was promoted not only in efforts to reduce demand, but also to ‘deal with the problems related to the transmission of’ HIV and other infectious diseases (Paragraph 17). This helped to

pave the way for the innovative ‘Beyond 2008’ project – a global consultation of civil society organisations from all sides of the debate coordinated by the Vienna NGO Committee on Drugs, in order to generate recommendations and a civil society declaration for the 2009 High-Level Meeting in Vienna.⁹⁶ More than 200 NGOs attended the event itself, and at least 11 NGO representatives were included in government delegations.⁹⁷ Many of the ‘Beyond 2008’ recommendations were eventually overlooked by member states, as there was no mechanism in place to integrate these proposals into the formal negotiation of the 2009 Political Declaration. Nevertheless, the Political Declaration gave more visibility to the issue of civil society participation than ever before – highlighting it in six paragraphs, including in Paragraph 10:

‘Welcome the important role played by civil society, in particular non-governmental organizations, in addressing the world drug problem, note with appreciation their important contribution to the review process, and note that representatives of affected populations and civil society entities, where appropriate, should be enabled to play a participatory role in the formulation and implementation of drug demand and supply reduction policy’

For the first time in Vienna, member states had agreed to take note of the role of ‘affected populations’ in drug policy design and implementation – and this has since been reiterated word-for-word in the 2014 Joint Ministerial Statement, and also echoed in the 2016 Outcome Document. NGO participation continued to go from strength to strength at the 2014 High-Level Meeting, where the first Informal Civil Society Hearing was held between civil society, governments and UN agencies, with conclusions presented at the plenary. But here again, there was no process established to incorporate these civil society recommendations into the 2014 Joint Ministerial Statement, and NGOs were not invited to observe the informal negotiations of the document.⁹⁸

A Civil Society Task Force (CSTF) was formed at the end of 2014 to serve as the official liaison between the UN and civil society in preparation for the 2016 UNGASS.⁹⁹ The CSTF was a structured group of civil society representatives from

nine regions, as well as representatives of affected populations and key thematic areas. The Task Force played a key role in coordinating and driving NGO participation and visibility at the UNGASS itself, which was attended by hundreds of NGO representatives working on a wide array of issues such as harm reduction, human rights, drug prevention, criminal justice, gender, palliative care and development. Civil society representatives were included in all five UNGASS panel discussions, and representatives also made interventions from the floor throughout. An Informal Interactive Stakeholder Consultation, convened by the President of the General Assembly, also took place in New York a few months before the UNGASS, and resulted in a forward-looking summary that was formally submitted to the CND as part of the preparatory process.¹⁰⁰ All of these efforts, like 'Beyond 2008', were designed to engage, represent and bring together the broad and conflicting perspectives held within civil society, which is far from a unitary actor in drug policy, and to build upon common ground where it could be found.

The continued and heightened engagement, professionalism and expertise from civil society was clearly reflected in the 2016 Outcome Document – where the role of civil society is highlighted in nine paragraphs relating to various elements of drug control and policy. These include sections on prevention and treatment (Paragraph 1q), development (Paragraphs 7b and 7l) and, for the first time, gender: Paragraph 4g includes strong language on the promotion of a 'gender perspective' and ensuring 'the involvement of women in all stages of the development, implementation, monitoring and evaluation of drug policies and programmes', without any diplomatic caveats. The Outcome Document also expands the role of civil society to include the provision of 'scientific evidence' in support of the 'evaluation of drug control policies and programmes'. The final paragraph also states:

'We resolve to take the necessary steps to implement the above-listed operational recommendations, in close partnership with the United Nations and other intergovernmental organizations and civil society...'

The focus for the 2019 Ministerial Segment three years later was, therefore, to consolidate and build on the gains made at UNGASS. The CSTF was revitalised and – for the first time ever – was specifically named in the modalities resolution for the high-level event.¹⁰¹ Civil society participation was cemented for the 'multi-stakeholder round tables', although space during the general plenary debate was at a premium due to time limitations. The CSTF also presented at the Ministerial Segment opening session, held a global online consultation for NGOs, and hosted 'civil society hearings' in New York and Vienna – the results of which were presented to member states in a Conference Room Paper formally submitted by Switzerland (as NGOs themselves are unable to submit).¹⁰²

The 2019 Ministerial Declaration itself made just two explicit references to civil society which, although welcome, were reiterations of previous language rather than any further steps forward: underscoring the important role played by civil society (paragraph 13), and 'supporting the Commission on Narcotic Drugs... fostering broad, transparent and inclusive discussions within the Commission, involving, as appropriate... civil society' (paragraph 24).

Criminal justice responses and the flexibilities within the conventions

The 1990 UNGASS took place two years after the passage of the 1988 Convention,¹⁰³ which sought to suppress violent, wealthy and powerful trafficking organisations that had grown in prominence during the 1980s. As such, the UNGASS discussions sought to provide impetus to the new Convention.¹⁰⁴ This involved strengthening the UN drug control system itself by intensifying criminal justice measures surrounding extradition, money laundering, judicial cooperation, precursor control, and so on – albeit within the principles of national sovereignty and the non-interference in the internal affairs of states (see, for example, Preambular Paragraph 5). This same messaging has remained relatively intact over time in the various UN high-level documents on drugs. Nevertheless, even as early as the 1990 Political Declaration, there has always been a degree of room

for alternative, health-oriented measures and an acknowledgement that such measures are permitted within all three international drug conventions. If these alternatives had been properly utilised and adopted by governments from the start, they would have fundamentally altered the way in which the drug control treaties are implemented – but in reality the uptake of such alternative measures has generally been poor.

Preparations for the 1998 UNGASS on drugs reflected the perceived need to further maintain, and even increase, the use of criminal sanctions: the president of Tajikistan referred to a ‘growing understanding of the need to fight against illegal drug trafficking – the plague of the twentieth century’.¹⁰⁵ Likewise, Interpol declared itself to be ‘adamantly opposed to any form of legalization of drugs, which would confer the status of legitimacy to illicit drugs or their abuse’ – although they did support alternatives to punishment ‘to wean the drug users away from crime, disease and misery’.¹⁰⁶

As a result of debates at the 2002 CND and the interventions of the INCB,¹⁰⁷ legal reforms relating to cannabis arose as a prominent topic during the 2003 Joint Ministerial Statement discussions – as noted in the official CND report: ‘Several speakers voiced their concern about lenient policies concerning cannabis, a substance controlled under the 1961 Convention. Cannabis was a harmful drug and it was argued that there were no good arguments for a more liberal policy towards it. It was noted that no Government had yet presented any evidence to WHO showing that cannabis should be legalized’.¹⁰⁸ This has remained the elephant in the room in many UN drugs debates right up until the present day – despite being a clear challenge to the criminal justice approach enshrined in the international drug conventions, and to the limits of any room for manoeuvre that is allowed within the conventions.¹⁰⁹

In the official foreword to the 2009 Political Declaration (and building on his 2008 report ‘Making drug control “fit for purpose”’¹¹⁰), the then-UNODC Executive Director Antonio Maria Costa stated: ‘We should invest in the solid middle ground between: (a) criminalization of drug users and (b) legalization of its use, by framing our collective efforts against drugs less like a war, and more like an effort to cure a social disease’. Yet the 2009

Political Declaration itself highlights that ‘There are limited alternatives to prosecution and imprisonment for drug-using offenders, and treatment services within the criminal justice system are frequently inadequate’ (Paragraph 15). The document goes on to state that criminal justice staff should be better educated to deal with people who use drugs, and that member states should ‘Provide appropriate training so that criminal justice and/or prison staff carry out drug demand reduction measures that are based on scientific evidence and are ethical and so that their attitudes are respectful, non-judgemental and non-stigmatizing’ (Paragraph 16d).

The 2016 Outcome Document represents a high point in these debates to date, calling on member states to strengthen ‘the capacity of health, social and law enforcement and other criminal justice authorities to cooperate... in the implementation of comprehensive, integrated and balanced responses’ (Paragraph 1l). In the chapter on ‘drugs and human rights, youth, children, women and communities’, under a sub-heading of ‘Proportionate and effective policies and responses...’, the Outcome Document also requests governments to: ‘Encourage the development, adoption and implementation... of alternative or additional measures with regard to conviction or punishment in cases of an appropriate nature’ (Paragraph 4j); and to consider sharing ‘best practices on the design, implementation and results of national criminal justice policies, including, as appropriate, domestic practices on proportional sentencing’ (Paragraph 4k). The 2016 UNGASS was also the first time that the explicit notion of ‘flexibility’ made it into a UN document of this import (Preambular Paragraph 13):

‘We recognize that there are persistent, new and evolving challenges that should be addressed in conformity with the three international drug control conventions, which allow for sufficient flexibility for States parties to design and implement national drug policies according to their priorities and needs, consistent with the principle of common and shared responsibility and applicable international law’

This direct reference to the principle of flexibility was prompted by global drug policy developments – and especially the adoption in several jurisdic-

tions of legally regulated cannabis cultivation, distribution and consumption. William Brownfield, the Assistant Secretary of State for the US Bureau of International Narcotic and Law Enforcement Affairs, opined in 2014 that ‘Things have changed... We must have enough flexibility to allow us to incorporate those changes into our policies... to tolerate different national drug policies, to accept the fact that some countries will have very strict drug approaches; other countries will legalize entire categories of drugs’.¹¹¹ This argument reflects the concept that the international conventions are living documents, the interpretation of which can adapt to meet changing contexts and circumstances.¹¹² But there are limits to how far such flexibility can reach:¹¹³ while the INCB made useful and supportive references to decriminalisation, proportionality of sentencing and alternatives to punishment,¹¹⁴ Brownfield and others saw that the US Government’s stance on regulated cannabis markets in several states fell within this flexibility (which it does not). In response to the issue of regulated markets for cannabis, the then-INCB President, Werner Sipp, stated that ‘flexibility has limits; it does not extend to any non-medical use of drugs. Recent legislative developments in some countries that permit and regulate the non-medical use of controlled substances, in particular cannabis, are in clear contravention of the conventions. They defy the international consensus upon which international cooperation depends. You – the States Parties to the conventions – have a responsibility to address this challenge’.¹¹⁵ As an example of this, Bolivia decided to withdraw from the 1961 Convention and then re-accede a year later with a reservation in order to establish a national regulated coca market based on indigenous and cultural use (a move unsuccessfully opposed at the time by the USA among others).¹¹⁶

The use of the term ‘sufficient flexibility’ in the preambular of the 2016 Outcome Document was a compromise between those seeking reforms, and those wishing to protect the integrity of the drug conventions: with the word ‘sufficient’ potentially serving to shut down attempts to revise or question the treaties themselves, or to promote policies and responses outside of those allowed by the conventions. A small group of countries opposed this language, but to no avail.¹¹⁷ This particular debate may be relatively new in

UN drug policy terms, but it was hoped that it would become a key battleground for future documents and meetings. However, the 2019 Ministerial Declaration failed to further develop these narratives – with member states instead eager to refer back to 2016 and previous commitments rather than reopen tensions on this issue.

Access to controlled medicines

Access to internationally controlled substances for medical and scientific purposes is one of the core objectives of the drug control regime enshrined in the three international drug conventions. Yet the 1990 Political Declaration was strongly focused on drug trafficking and crime instead, with little reference to access to controlled medicines. The accompanying Plan of Action, states that ‘information on the rational prescribing and use’ should be included in medical training (Paragraph 23), and that ‘WHO, in collaboration with UN drug control bodies’, NGOs and others are ‘encouraged to assist national educational authorities in developing training courses and conducting training courses to ensure that medical practitioners and other health personnel are well trained in rational prescribing and use of narcotic drugs and psychotropic substances’ (Paragraph 24). Paragraphs 40 and 41 also call for a balance between supply and demand of raw materials, including for medical and scientific purposes, and for international action to help states meet their legitimate needs for opiates. Eight years later, however, the 1998 Political Declaration made no reference to these issues.

The 2003 Joint Ministerial Statement reiterated calls for member states to balance supply and demand for opiate raw materials for medical and scientific purposes, linked to the necessity to avoid a proliferation of sources of production. The 2009 Political Declaration supplemented this idea of balance with a call for ‘continued cooperation between Member States, the INCB and WHO to ensure the adequate availability of narcotic drugs and psychotropic substances under international control, including opiates, for medical and scientific purposes’ (Paragraph 19).

At the 2014 High-Level Meeting, there was more visibility and discussion on access to medicines

than ever before, driven in part by increased attention to this issue and the role of the INCB from some civil society actors. The Joint Ministerial Statement again reiterated the need for adequate supplies of controlled drugs, and this time added its ‘concern that the availability of internationally controlled drugs for medical and scientific purposes, particularly for the relief of pain and for palliative care, remains low to non-existent in many countries of the world’ (Paragraph 14). It further called for the WHO and the UN drug control bodies ‘to address that situation by promoting measures to ensure their availability and accessibility for medical and scientific purposes’. It is notable that these references to ensuring access to control drugs for medical and scientific purposes were, between 2009 and 2014, appended routinely with the stipulation ‘while simultaneously preventing their diversion, abuse and trafficking’.

Also in 2014, the debate around ketamine resurfaced and placed access to medicines firmly on the agenda. Through CND Resolution 57/10 on ‘Preventing the diversion of ketamine from legal sources, while ensuring availability for medical use’, China, Egypt, India, Thailand and others sought to encourage member states to increase controls over this essential medicine¹¹⁸ – thus undermining the WHO’s Expert Committee on Drug Dependence (ECDD) which had recommended against the scheduling of ketamine in order to avoid a ‘public health crisis’ due to its crucial role in emergency surgery in resource-poor settings.¹¹⁹ At the 2015 CND, China formally tabled the proposal to schedule ketamine against the ECDD’s advice – but eventually withdrew the proposal pending further evidence and review from the ECDD (following a strong campaign by civil society, clinicians and supportive member states).¹²⁰

These developments, and improvements in the collaboration between the WHO and the INCB,¹²¹ helped to frame the preparations for the 2016 Outcome Document – which contains the most comprehensive language to date on access to controlled medicines. The Outcome Document acknowledged the ‘low to non-existent’ supplies of controlled substances for medical and scientific purposes around the world, and dedicates an entire thematic chapter to this issue, for the first time containing a series of ‘operational recom-

mendations’ (Paragraph 2). The first of these deals with existing barriers to access, ‘including those related to legislation, regulatory systems, health-care systems, affordability, the training of health-care professionals, education, awareness-raising, estimates, assessment and reporting, benchmarks for consumption of substances under control, and international cooperation and coordination’. The 2016 Outcome Document also calls on member states to, inter alia: ‘consider reviewing... domestic legislation and regulatory and administrative mechanisms’; streamline and simplify distribution channels; remove current impediments; improve import and export certification; and address the costs of medicines. The WHO and the UNODC are also requested to engage in capacity building for national authorities, develop national supply systems, and regularly update the Model List of Essential Medicines.¹²² Even in the separate chapter addressing new psychoactive substances, the Outcome Document cites the need to review the ‘potential uses of new psychoactive substances for medical and scientific purposes’ (Paragraph 5d).

The 2019 Ministerial Declaration was, by design, a much shorter document than its predecessors (seeking to allude to previous commitments rather than relist or reframe them) – yet it explicitly acknowledged that the ‘availability of internationally controlled substances for medical and scientific purposes, including for the relief of pain and palliative care, remains low to non-existent in many parts of the world’ (paragraph 17 – ‘Stocktaking’). In the Declaration, member states therefore chose to ‘reiterate our resolve... to ensure access to and the availability of controlled substances for medical and scientific purposes, including for the relief of pain and suffering, and address existing barriers in this regard, including affordability’.

UN system-wide coherence

Despite the cross-cutting nature of the ‘world drug problem’, the Vienna-based institutions (i.e. the CND, the UNODC and the INCB) have historically excluded or marginalised other UN bodies from their deliberations. This has been particularly troubling with regards to the WHO, despite

their treaty-mandated role in drug policy. The absence of cross-UN engagement has resulted in a lack of UN system-wide coherence between drug control and other branches of the UN – not least public health, human rights and development,¹²³ and this has been clearly reflected in the high-level UN documents that are the focus of this paper. This is despite recent progress in this area, with the adoption, in November 2018, of the UN System Common Position on drugs by the heads of all 31 UN agencies, enabling them to speak with one voice on drug policy matters.¹²⁴

Surprisingly, the 1990 Political Declaration was one of the strongest high-level documents in terms of encouraging UN coherence. It called for the participation of a wide range of UN institutions in drug policy governance – including the ILO, UNICEF, UNDP, UNEP and WHO. The document also explicitly emphasized the need for UN system-wide coherence on drugs, albeit with generic language on the role that other agencies could play.

The 1993 General Assembly Resolution was significantly weaker in this regard – omitting any specific reference to other UN agencies, although it does mention the UN System-Wide Action Plan (SWAP) on Drug Abuse Control. The SWAP, in many ways a high watermark in cross-UN coordination efforts on drugs, was requested in 1989 by the General Assembly with the aim of enhancing the ‘effectiveness of the United Nations system in the field of drug abuse control’.¹²⁵ Yet any mention of wider UN system engagement had disappeared by the time the 1998 Political Declaration was adopted.

In 2001, the roles of the SWAP were transferred to the UNODC, with a negative impact on UN system-wide coherence on drugs.¹²⁶ References to wider UN engagement returned in the 2003 Joint Ministerial Statement: ‘We call upon the relevant United Nations agencies and entities, other international organizations and international financial institutions, including regional development banks, to mainstream drug control issues into their programmes’ (Paragraph 16). However, the document fell short of mentioning any specific UN agency and approaches coherence as a one-way street – disregarding the problematic absence of health, human rights, development or environmental concerns within drug policies

themselves.

The tide began to turn with the 2009 Political Declaration: Paragraph 2e of the Plan of Action encouraged the creation of dialogue between the UNODC and the INCB with UNAIDS, UNDP and the WHO in order to ‘strengthen inter-agency cooperation’. However, this still fell short of the 1990 Political Declaration language – lacking precision and failing to describe how this inter-agency cooperation was to be achieved. For example, Section D of the Plan of Action on alternative development reiterated the importance of the Millennium Development Goals,¹²⁷ but failed to promote greater cooperation with UNDP.

Preparations for the 2016 UNGASS were marked by a more structured inclusion of the UN agencies based in New York and Geneva: through the UN Task Force on Transnational Organized Crime and Drug Trafficking.¹²⁸ The Task Force invited all agencies to participate and make submissions ahead of the meeting itself. Their submissions were broadly progressive in their support of harm reduction, decriminalisation of drug use, gender, etc.¹²⁹ The UN Women submission, for example, states that:

‘UN Women shares the main messages of the task force and the UN system’s approach to the world drug problem: that an emphasis on security, criminal justice, and law enforcement have only yielded mixed results at substantial human security and financial cost; that a greater emphasis on the public health dimensions and the socioeconomic consequences of the problem is preferable; that member states should avoid militarizing counter-trafficking measures and criminalizing the most vulnerable in the chain of drug production and drug trafficking, including the possibility of decriminalizing drug use and low-level, non-violent drug offenses; that eradication efforts will not succeed without alternative economic incentives for affected populations; that the world drug problem needs to be addressed, in sum, in a more balanced and humane way, prioritizing evidence-based, health-centered approaches focused on prevention, treatment, and social rehabilitation and integration, and addressing both supply and demand’.¹³⁰

As well as formal submissions,¹³¹ UN agencies were also vocal and visible in the thematic debates before and at the UNGASS itself – and such unprecedented cross-UN inputs are widely regarded as one of the major ‘wins’ from the UNGASS.¹³² It is therefore no coincidence that the 2016 Outcome Document represents a significant improvement over previous documents in relation to cross-UN engagement. It puts forward the strongest support of the WHO’s role to date, and the preamble emphasizes the need to strengthen cooperation between drug control institutions and ‘other UN entities within their respective mandates’. With regards to alternative development, Paragraph 7d considers elaborating programmes alongside FAO, ILO and UNDP in the context of achieving the Sustainable Development Goals (which themselves ‘can only be realized with a strong commitment to global partnership and cooperation’¹³³). However, the Outcome Document goes beyond merely mentioning branches of the UN: Paragraph 4 outlines a wide range of other UN conventions and guidelines that are relevant to making drug policy respectful of human rights and public health. Since the UNGASS, this commitment to increased UN system-wide engagement has been maintained – with the heightened visibility of several UN agencies at CND discussions (including the presence of the then-WHO Executive Director, Margaret Chan, on the podium at the 60th session of the CND in March 2017¹³⁴), and the signature of a new Memorandum of Understanding between the UNODC and the WHO.¹³⁵

The most significant development in terms of UN system-wide coherence in the lead up to the 2019 Ministerial Segment was, without question, the UN System Common Position on drug policy – launched, as mentioned above, in late 2018 on behalf of all 31 UN entities.¹³⁶ The Common Position represented a significant step forward: a progressive, strong and united message from the UN system, under the auspices of Secretary-General António Guterres (who also delivered a video statement at the opening of the Ministerial Segment itself). UN agencies including the UNODC, the WHO and the OHCHR committed to ‘harnessing synergies and strengthening inter-agency cooperation, making best use of the expertise within the United Nations system’. The Common Position also created an inter-agency Task Team

to follow-up and assess implementation going forward, and this Task Team submitted a further report in time for the 2019 Ministerial Segment – entitled ‘What we have learned over the last ten years: A summary of knowledge acquired and produced by the UN system on drug-related matters’.¹³⁷

However, new language from the Common Position and Task Team did not transfer into the 2019 Ministerial Declaration itself – although the Declaration did repeat previous commitments to ‘encourage further contributions of relevant United Nations entities... to the work of the Commission and the efforts of Member States’, to ‘strengthen international and inter-agency cooperation’, and ‘enhance coherence within the United Nations system at all levels’.

Conclusion

‘The consensus-driven functioning of the UN drug control machinery has led to strange results... In private, “most authorities agree that it is unrealistic to expect to eradicate drugs” and that the present regime is ineffective. But as soon as they sit down in the conference halls in Vienna and New York, they shift into consensus mode and the majority of officials are swept along in a ritual of rhetoric while the minority prefers to keep as low a profile as possible’.¹³⁸

In many respects, the increasingly long and tense diplomatic negotiations underpinning each of the high-level UN documents compared in this paper¹³⁹ can be criticised for their disconnect from the reality on the ground that they purport to represent – as well as the existing divide between progressive statements made by member states and consensus-based UN documents. But the language agreed by the UN drug control structures can be an effective force in driving policy change at the national and regional levels. Even though the pace may be glacial, shifts over time in the agreed language are important, and are integral to the normative role played by UN agencies such as the UNODC.

This paper has identified some areas for which recent high-level documents represent clear progress in terms of the UN discourse, the con-

sensus-based language and the general debates: such as human rights, development approaches, civil society engagement, flexibilities in the international drug conventions, access to controlled medicines, and cross-UN engagement. That is not to say that further progress is not still needed in all of these areas, but some of the trends identified in this report serve as an important proxy for overall shifts in drug control debates and approaches around the world. Key elements of this progress include the more systematic engagement of both civil society and UN agencies in the preparations and discussions, the relatively coordinated work of groups of like-minded countries, and the adoption of a more comprehensive document structure – with the UNGASS Outcome Document utilising seven chapters (including public health, alternative development, access to medicines and human rights) rather than the previous three (demand reduction, supply reduction and international cooperation) – or the Ministerial Segment looking back at progress made and ongoing challenges in a ‘stocktaking’ section, to then look to the future. If progress is to continue, these are all elements of the preparations that need to be protected and strengthened further.

Then there is the long-term tension and controversy over harm reduction. The fact that member states have still been unable to agree on this term is unjustifiable and damaging to the credibility of the entire UN drug control system – not least because other parts of the UN, including all of the relevant UN agencies and even the UN General Assembly itself when discussing the HIV response, have overcome this – including at the High Level Meeting on HIV/AIDS which took place only two months after the 2016 UNGASS on drugs. Although the latest UNGASS did present us with the strongest language to date on specific harm reduction interventions, arguably the most straight-forward language on the broader principle of harm reduction can still be found in the 1990 Political Declaration: ‘health education programmes and policies for the reduction of risk and harm of drug abuse’.

Similarly, it is highly problematic that the 2019 Ministerial Segment (and subsequent CND resolutions) fails to mention the UN System Common Position – a critical document for ensuring more coherence and collaboration on drug policy is-

sues within the UN family as a whole.

Even where progress has been made, it is the role of civil society to continue pushing for more, and to ensure that shifting narratives are translated into changes on the ground and not confined to laudable but rhetorical exchanges in UN meeting rooms.¹⁴⁰ ‘Reformers looking towards a new era of humane and evidence-informed drug policy must know how to look beyond rhetorical commitments to public health to implementation of effective programs’.¹⁴¹

This paper demonstrates the progress that has been made in several areas of UN drug control discussions. This remains important in the current drug policy debates, where there has been a clear tension between member states who wanted to revert to language and tone from the 2009 Political Declaration, and those who wanted to emphasise the importance of the more progressive and more recent 2016 Outcome Document.¹⁴² There remains much work to be done to deliver an international drug policy that is truly and meaningfully based on public health, development and human rights. However, there is much progress, in particular in the 2016 UNGASS Outcome Document, that now needs to be consolidated, repeated and further developed in the coming years.

Acknowledgements

The authors wish to thank Catherine Cook, Olga Szubert and colleagues from Harm Reduction International for their comments on the first version of this paper, as well as Marie Nougier and Ann Fordham from IDPC for their detailed inputs, reviews and editing.

Endnotes

1 Interestingly, the term ‘world drug problem’ itself has never been clearly defined in any of the UN texts – yet remains widely used

2 See: <http://www.unodc.org/ungass2016/>

3 See, for example: International Drug Policy Consortium (September 2016), *The UNGASS on the world drug problem: Report of proceedings*, <http://idpc.net/>

- publications/2016/09/the-ungass-on-the-world-drug-problem-report-of-proceedings; Bewley-Taylor, D. & Jelsma, M. (June 2016), *UNGASS 2016: A broken or b-r-o-a-d consensus?* Drug policy briefing 45 (Transnational Institute & Global Drug Policy Observatory), http://www.swansea.ac.uk/media/Broken%20or%20broad_FINAL.pdf
- 4 United Nations Secretary-General (26 June 2013), *Secretary-General's remarks at special event on the International Day against Drug Abuse and illicit Trafficking*, <http://www.un.org/sg/statements/index.asp?nid=6935>
- 5 Commission on Narcotic Drugs (2009), *Political Declaration and Plan of Action on international cooperation towards an integrated and balanced strategy to counter the world drug problem*, https://www.unodc.org/documents/commissions/CND/Political_Declaration/Political_Declaration_2009/Political-Declaration2009_V0984963_E.pdf
- 6 Commission on Narcotic Drugs (2019), *Ministerial declaration on strengthening our actions at the national, regional and international levels to accelerate the implementation of our joint commitments to address and counter the world drug problem*, https://www.unodc.org/documents/commissions/CND/2019/Ministerial_Declaration.pdf
- 7 General Assembly (1990), *S-17/2. Political Declaration and Global Programme of Action adopted by the General Assembly at its seventeenth special session, devoted to the question of international co-operation against illicit production, supply, demand, trafficking and distribution of narcotic drugs and psychotropic substances*, https://www.unodc.org/documents/commissions/CND/Political_Declaration/Political_Declaration_1990/1990_Political_Declaration_and_Programme_of_Action.pdf
- 8 General Assembly (1993), *Measures to strengthen international cooperation against the illicit production, sale, demand, traffic and distribution of narcotic drugs and psychotropic substances and related activities*, A/RES/48/12, <http://www.un.org/documents/ga/res/48/a48r012.htm>
- 9 General Assembly (1998), *S-20/2. Political Declaration*, A/RES/S-20/2*, https://www.unodc.org/documents/commissions/CND/Political_Declaration/Political_Declaration_1998/1998-Political-Declaration_A-RES-S-20-2.pdf
- 10 General Assembly (1998), *Declaration on the guiding principles of drug demand reduction*, <http://www.un.org/ga/20special/demand.htm>
- 11 Commission on Narcotic Drugs (2003), *Joint Ministerial Statement and further measures to implement the action plans emanating from the twentieth special session of the General Assembly*, E/CN.7/2003/L.23/Rev.1, https://www.unodc.org/unodc/en/commissions/CND/session/46_Session_2003/CND_46_Session.html
- 12 Commission on Narcotic Drugs (2009), *Political Declaration and Plan of Action on international cooperation towards an integrated and balanced strategy to counter the world drug problem*, https://www.unodc.org/documents/commissions/CND/Political_Declaration/Political_Declaration_2009/Political-Declaration2009_V0984963_E.pdf
- 13 Commission on Narcotic Drugs (2014), *Joint Ministerial Statement – 2014 high-level review by the Commission on Narcotic Drugs of the implementation by member states of the Political Declaration and Plan of Action on international cooperation towards an integrated and balanced strategy to counter the world drug problem*, https://www.unodc.org/documents/hlr/JointStatement/V1403583_E_ebook.pdf
- 14 General Assembly (2016), *Outcome document of the 2016 United Nations General Assembly Special Session on the world drug problem – Our joint commitment to effectively addressing and countering the world drug problem*, <https://www.unodc.org/documents/postungass2016/outcome/V1603301-E.pdf>
- 15 Commission on Narcotic Drugs (2019), *Ministerial declaration on strengthening our actions at the national, regional and international levels to accelerate the implementation of our joint commitments to address and counter the world drug problem*, https://www.unodc.org/documents/commissions/CND/2019/Ministerial_Declaration.pdf
- 16 Arlacchi, P. (Summer 1998), 'Towards a drug-free world by 2008 – We can do it', *UN Chronicle*, **35**(2)
- 17 Jelsma, M. (2003), *The unwritten history of the 1998 United Nations General Assembly Special Session on Drugs* (Transnational Institute), <https://www.tni.org/en/article/the-unwritten-history-of-the-1998-united-nations-general-assembly-special-session-on-drugs>
- 18 Costa, A.M. (May 2008), "Making drug control 'fit for purpose': Building on the UNGASS decade" - Report by the Executive Director of the United Nations Office on Drugs and Crime as a contribution to the review of the twentieth special session of the General Assembly, E/CN.7/2008/CRP.17*, https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_51/1_CRPs/E-CN7-2008-CRP17_E.pdf
- 19 International Drug Policy Consortium (January 2015), *IDPC response to the 2014 UNODC World Drug Report*, <http://idpc.net/publications/2015/01/idpc-response-to-the-2014-unodc-world-drug-report>
- 20 General Assembly (July 2011), *Resolution 65/277. Political Declaration on HIV and AIDS: Intensifying our efforts to eliminate HIV and AIDS*, A/RES/65/277), http://www.unaids.org/sites/default/files/sub_landing/files/20110610_UN_A-RES-65-277_en.pdf
- 21 Joint United Nations Programme on HIV and AIDS (2016), *Get on the fast-track – The life-cycle approach to HIV*, <http://www.unaids.org/en/resources/documents/2016/get-on-the-fast-track>
- 22 United Nations Development Programme (March 2015), *Perspectives on the development dimensions of drug control policy*, www.unodc.org/documents/ungass2016/Contributions/UN/UNDP/UNDP_paper_for_CND_

March_2015.pdf

23 International Drug Policy Consortium (September 2019), *The 2019 Ministerial Segment: Key wins, remaining challenges, and next steps for advocacy*, <https://idpc.net/publications/2019/09/the-2019-ministerial-segment-key-wins-remaining-challenges-and-next-steps-for-advocacy>

24 Commission on Narcotic Drugs (June 2019), *Implementation of all our international drug policy commitments, following up to the 2019 Ministerial Declaration “Strengthening our actions at the national, regional and international levels to accelerate the implementation of our joint commitments to address and counter the world drug problem” – Multiyear workplan*, https://www.unodc.org/documents/commissions/CND/2019/Follow-up_to_2019_Ministerial_Declaration/Intersessional_Meetings/CND_Workplan_2019-2023.pdf

25 See: General Assembly (August 2001), *Resolution S-26/2. Declaration of commitment on HIV/AIDS*, A/RES/S-26/2, <http://www.un.org/ga/aids/docs/aress262.pdf>; General Assembly (March 2006), *Declaration of commitment on HIV/AIDS: Five years later*, A/60/736, http://www.unaids.org/sites/default/files/sub_landing/files/20060324_sgreport_ga_a60737_en.pdf; General Assembly (July 2011), *Resolution 65/277. Political Declaration on HIV and AIDS: Intensifying our efforts to eliminate HIV and AIDS*, A/RES/65/277), http://www.unaids.org/sites/default/files/sub_landing/files/20110610_UN_A-RES-65-277_en.pdf

26 General Assembly (July 2011), *Resolution 65/277. Political Declaration on HIV and AIDS: Intensifying our efforts to eliminate HIV and AIDS*, A/RES/65/277), http://www.unaids.org/sites/default/files/sub_landing/files/20110610_UN_A-RES-65-277_en.pdf

27 General Assembly (2016), *Resolution 70/266. Political Declaration on HIV and AIDS: On the fast track to accelerating the fight against HIV and to ending the AIDS epidemic by 2030*, A/RES/70/266, <http://www.unaids.org/en/resources/documents/2016/2016-political-declaration-HIV-AIDS>

28 United Nations Office on Drugs and Crime, International Network of People Who Use Drugs, Joint United Nations Programme on HIV/AIDS, United Nations Development Programme, United Nations Population Fund, World Health Organization, and United States Agency for International Development (2017), *Implementing comprehensive HIV and HCV programmes with people who inject drugs: practical guidance for collaborative interventions*, <http://bit.ly/2oghaxx>

29 United Nations Chief Executives Board (November 2018), *United Nations system common position supporting the implementation of the international drug control policy through effective inter-agency collaboration*, CEB/2018/2, http://fileserv.idpc.net/library/CEB-2018-2-SoD_Common-position.pdf

30 <http://cndblog.org/maps/harm-reduction/>

31 Harm Reduction International (2016), *Global state of harm reduction 2016*, <https://www.hri.global/contents/1739>

32 Jelsma, M. (2003), *The unwritten history of the 1998 United Nations General Assembly Special Session on Drugs* (Transnational Institute), <https://www.tni.org/en/article/the-unwritten-history-of-the-1998-united-nations-general-assembly-special-session-on-drugs>

33 United Nations, *General Assembly twentieth special session, 6th plenary meeting, Tuesday 9 June 1998*, A/S-20/PV.6, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.6&Lang=E

34 United Nations, *General Assembly twentieth special session, 8th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.8, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.8&Lang=E

35 United Nations, *General Assembly twentieth special session, 9th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.9, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.9&Lang=E

36 See: <https://www.globalcommissionondrugs.org/about-us/mision-and-history/commissioners/>

37 United Nations, *General Assembly twentieth special session, 9th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.9, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.9&Lang=E

38 United Nations, *General Assembly twentieth special session, 8th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.8, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.8&Lang=E

39 General Assembly (February 2000), *Resolution 54/132. International cooperation against the world drug problem*, A/RES/54/132, https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/1990-1999/1999/GA_A-RES-54-132.pdf

40 UNDCP Legal Affairs Section (2002), *Flexibility of treaty provisions as regards harm reduction approaches*, <http://www.druglawreform.info/en/issues/harm-reduction/item/372-flexibility-of-treaty-provisions>; Transnational Institute (March 2005), *The United Nations and harm reduction*, Drug policy briefing Nr. 12, <http://www.druglawreform.info/images/stories/brief12.pdf>

41 See: <http://idpc.net/publications/2004/08/dear-bobby-unodc-letter-on-harm-reduction>. For a full account of the debates about harm reduction, see: Transnational Institute (March 2005), *The United Nations and harm reduction*, Drug policy briefing No 12, <http://www.druglawreform.info/images/stories/brief12.pdf>; Jelsma, M. (April 2005), *The UN and harm reduction – Revisited. An unauthorised report on the outcomes of the 48th CND session*, Drug policy briefing Nr. 13 (Transnational Institute), <http://druglawreform.info/en/publications/drug-policy-briefings/item/2303-the-un-and-harm-reduction-revisited>

42 World Health Organization, United Nations Office on Drugs and Crime & Joint United Nations Programme on HIV and AIDS (2009), *WHO, UNODC, UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users*, https://www.unodc.org/documents/hiv-aids/idu_target_

setting_guide.pdf – updated in 2012, see: http://www.who.int/hiv/pub/idu/targets_universal_access/en/

43 International Drug Policy Consortium (April 2009), *IDPC report of proceedings: The 2009 Commission on Narcotic Drugs and High Level Segment*, <http://idpc.net/publications/2009/04/idpc-proceedings-document-on-2009-cnd-high-level-segment>

44 Germany spoke on behalf of Australia, Bolivia, Bulgaria, Croatia, Cyprus, Estonia, Finland, Georgia, Greece, Hungary, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Saint Lucia, Slovenia, Spain, Switzerland and the United Kingdom

45 Commission on Narcotic Drugs (2009), *Report of the fifty-second session (14 March 2008 and 11-20 March 2009)*, E/CN.7/2009/12, <http://www.un.org/Docs/journal/asp/ws.asp?m=E/2009/28>. Also see discussion of this in: Bewley-Taylor, D. (2012), *International drug control: Consensus fractured* (Cambridge University Press)

46 International Drug Policy Consortium (June 2014), *The 2014 Commission on Narcotic Drugs and its High-Level Segment: Report of proceedings*, <http://idpc.net/publications/2014/06/the-2014-commission-on-narcotic-drugs-and-its-high-level-segment-report-of-proceedings>

47 Commission on Narcotic Drugs (2014), *Report of the fifty-seventh session (13 December 2013 and 13-21 March 2014)*, E/CN.7/2014/16, <http://www.un.org/Docs/journal/asp/ws.asp?m=E/2014/28>

48 <http://cndblog.org/maps/harm-reduction/>

49 International Drug Policy Consortium (April 2016), *Diplomacy or denialism? The language that the UNGASS Outcome Document overlooked*, Press release, <http://idpc.net/media/press-releases/2016/04/diplomacy-or-denialism-the-language-that-the-ungass-outcome-document-overlooked>

50 Hallam, C. (March 2016), *Striving for system-wide coherence: An analysis of the official contributions of United Nations entities for the UNGASS on drugs* (International Drug Policy Consortium), <http://idpc.net/publications/2016/03/striving-for-system-wide-coherence-an-analysis-of-the-official-contributions-of-united-nations-entities-for-the-ungass-on-drugs>

51 Hunt, P. UN Special Rapporteur on the right to the highest attainable standard of health (2008), *Human rights, health and harm reduction – States' amnesia and parallel universes*, <https://www.hri.global/files/2010/06/16/HumanRightsHealthAndHarmReduction.pdf>

52 United Nations, *General Assembly twentieth special session, 1st plenary meeting, Monday 8 June 1998*, A/S-20/PV.1, p. 21, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.1&Lang=E

53 United Nations, *General Assembly twentieth special session, 1st plenary meeting, Monday 8 June 1998*, A/S-20/PV.1, p. 3, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.1&Lang=E

57 United Nations, *General Assembly twentieth special session, 5th plenary meeting, Tuesday 9 June 1998*, A/S-20/

PV.5, p. 16, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.5&Lang=E

55 United Nations, *General Assembly twentieth special session, 9th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.9, p. 25, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.9&Lang=E

56 Commission on Narcotic Drugs (2008), *Resolution 51/12. Strengthening cooperation between the United Nations Office on Drugs and Crime and other United Nations entities for the promotion of human rights in the implementation of the international drug control treaties*, http://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2000-2009/2008/CND_Res-2008-12e.pdf

57 International Drug Policy Consortium (April 2008), *IDPC Briefing Paper number 8 – Report on proceedings at the 2008 Commission on Narcotic Drugs*, <http://idpc.net/publications/2008/04/report-on-proceedings-at-2008-commission-on-narcotic-drugs>

58 Ibid

59 Harm Reduction International (April 2008), *The life of a human rights resolution at the UN Commission on Narcotic Drugs*, <https://www.hri.global/contents/288>

60 See: International Drug Policy Consortium (June 2014), *The 2014 Commission on Narcotic Drugs and its High-Level Segment. Report of proceedings*, pp. 1-2 & 6, <http://idpc.net/publications/2014/06/the-2014-commission-on-narcotic-drugs-and-its-high-level-segment-report-of-proceedings>

61 Commission on Narcotic Drugs (2014), *Report of the fifty-seventh session (13 December 2013 and 13-21 March 2014)*, E/CN.7/2014/16, pp. 61-2, <http://www.un.org/Docs/journal/asp/ws.asp?m=E/2014/28>

62 Albania, Andorra, Argentina, Armenia, Australia, Bosnia and Herzegovina, Chile, Colombia, Costa Rica, El Salvador, Haiti, Iceland, Kazakhstan, Liechtenstein, Macedonia, Mexico, Monaco, Montenegro, Namibia, New Zealand, Panama, Republic of Moldova, San Marino, Serbia, Sierra Leone, Switzerland, Turkey, Ukraine, Uruguay and Uzbekistan

63 Commission on Narcotic Drugs (2014), *Report of the fifty-seventh session (13 December 2013 and 13-21 March 2014)*, E/CN.7/2014/16, p. 61, <http://www.un.org/Docs/journal/asp/ws.asp?m=E/2014/28>

64 Bahrain, China, Egypt, Indonesia, Kuwait, Libya, Malaysia, Oman, Qatar, Saudi Arabia, Singapore, the Sudan, the Syrian Arab Republic, the United Arab Emirates, Viet Nam and Yemen

65 <http://cndblog.org/maps/death-penalty/>

66 See: International Drug Policy Consortium (2015), *The 2015 Commission on Narcotic Drugs and its Special Session on Preparations for the United Nations General Assembly Special Session on the World Drug Problem – Report of Proceedings*, <http://idpc.net/publications/2015/06/the-2015-commission-on-narcotic-drugs-and-its-special-session-on-preparations-for-the-ungass-on-the-world>

drug-problem-report-of-proceedings; International Drug Policy Consortium (2016), *The 2016 Commission on Narcotic Drugs and its Special Session on Preparations for the UNGASS on the World Drug Problem – Report of Proceedings*, <http://idpc.net/publications/2016/07/the-2016-commission-on-narcotic-drugs-and-its-special-segment-on-preparations-for-the-ungass-on-the-world-drug-problem>; International Drug Policy Consortium (September 2016), *The UNGASS on the world drug problem: Report of proceedings*, p. 4, <http://idpc.net/publications/2016/09/the-ungass-on-the-world-drug-problem-report-of-proceedings>. For more discussion of UNGASS, also see the Official Records: <http://www.un.org/en/ga/sessions/special.shtml>

67 United Nations, *General Assembly thirtieth special session, 1st plenary meeting, Tuesday 19 April 2016, A/S-30/PV.1*, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-30/PV.1

68 The 28 European Union member states, Albania, Andorra, Argentina, Australia, Bosnia and Herzegovina, Canada, Cabo Verde, Chile, Colombia, El Salvador, Georgia, Iceland, Liechtenstein, Macedonia, Mexico, Moldova, Monaco, Montenegro, Namibia, New Zealand, Norway, Panama, San Marino, Serbia, Turkey, Ukraine, Uruguay and Uzbekistan

69 China, Singapore, Yemen, Malaysia, Pakistan, Egypt, Saudi-Arabia, Oman, the UAE, Qatar, Kuwait, Bahrain, Iran and Sudan

70 Human Rights Council (April 2015), *Resolution 28/28. Contribution of the Human Rights Council to the special session of the General Assembly on the world drug problem of 2016*, A/HRC/RES/28/28, http://ap.ohchr.org/documents/alldocs.aspx?doc_id=24820

71 See: Office of the High Commissioner for Human Rights (September 2015), *Study on the impact of the world drug problem on the enjoyment of human rights*, A/HRC/30/65, http://www.ohchr.org/EN/HRBodies/HRC/RegularSessions/Session30/Documents/A_HRC_30_65_E.docx

72 Lines, R. & Barret, D. (May 2016), *The human rights 'win' at the UNGASS on drugs that no one is talking about, and how we can use it*, University of Essex, Human Rights Centre blog, <https://hrcessex.wordpress.com/2016/05/09/the-human-rights-win-at-the-ungass-on-drugs-that-no-one-is-talking-about-and-how-we-can-use-it/>

73 See, for example: Burger, J. & Kapron, M. (June 2017), 'Drug policy and indigenous peoples', *Health and Human Rights Journal*, 19(1): 269-278, <http://cdn2.sph.harvard.edu/wp-content/uploads/sites/13/2017/06/Burger.pdf>

74 Jamaica proposed during the 2016 UNGASS negotiations to include: 'Respect the licit uses of plants containing psychoactive substances for traditional, cultural and religious practices, as recognised in the 1971 Convention on Psychotropic Substances and the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, in accordance with applicable human rights obligations and the United Nations Declaration on the Rights of Indigenous Peoples'

75 Zeid Ra'ad Al Hussein, *Statement by Zeid Ra'ad Al Hussein, United Nations High Commissioner for Human Rights*, Round Table 3: Cross-cutting issues - drugs and human rights, youth, women, children and communities, 30th Special Session on World Drug Problem, General Assembly, 20 April 2016, <http://webtv.un.org/meetings-events/general-assembly/watch/round-table-3-30th-special-session-on-world-drug-problem-general-assembly/4855628109001>

76 Article 14/2, 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, https://www.unodc.org/pdf/convention_1988_en.pdf

77 United Nations Office on Drugs and Crime (January 2013), *Bolivia to re-accede to UN drug convention, while making exception on coca leaf chewing*, <https://www.unodc.org/unodc/en/frontpage/2013/January/bolivia-to-re-accede-to-un-drug-convention-while-making-exception-on-coca-leaf-chewing.html>

78 See, for instance: Human Rights Council (2018), *Resolution 37/42. Contribution to the implementation of the joint commitment to effectively addressing and countering the world drug problem with regard to human rights*, A/HRC/RES/37/42, https://ap.ohchr.org/documents/dpage_e.aspx?si=A/HRC/RES/37/42; Human Rights Council (2019), *Resolution 42/22. Arbitrary detention*, /HRC/RES/42/22 <https://undocs.org/en/A/HRC/RES/42/22>; Human Rights Council (2019), *Resolution 41/2. Promotion and protection of human rights in the Philippines*, A/HRC/RES/41/2, <https://undocs.org/A/HRC/RES/41/2>; Human Rights Council (2020), *Resolution 45/33. Technical cooperation and capacity-building for the promotion and protection of human rights in the Philippines*, A/HRC/RES/45/33, <https://undocs.org/en/A/HRC/RES/45/33>; Human Rights Council (2019), *Resolution 42/24. The question of the death penalty*, A/HRC/RES/42/24, <https://undocs.org/A/HRC/RES/42/24>

79 Amongst many others, see the following Concluding Observations of the Committee on the Elimination of Discrimination Against Women: CEDAW/C/SYC/CO/6 (2019 Review of the Seychelles); CEDAW/C/KHM/CO/6 (2019 Review of Cambodia); CEDAW/C/CHL/CO/7 (2018 Review of Chile); CEDAW/C/MNE/CO/2 (2017 Review of Montenegro); CEDAW/C/LKA/CO/8 (2017 Review of Sri Lanka); see also the following Concluding Observations of the Committee on Economic, Social and Cultural Rights: E/C.12/ECU/CO/4 (2019 review of Ecuador)

80 Office of the High Commissioner for Human Rights (14 September 2018), *Implementation of the joint commitment to effectively addressing and countering the world drug problem with regard to human rights**, A/HRC/39/39, http://fileservr.idpc.net/library/A_HRC_39_39.pdf

81 Jelsma, M. (December 2019), *UN Common Position on Drug Policy: Consolidating system-wide coherence* (International Drug Policy Consortium and Transnational Institute), <https://idpc.net/publications/2019/12/un-common-position-on-drug-policy-consolidating-system-wide-coherence>

82 United Nations Drug Control Programme (September 1993), *Technical information paper, Alternative development as an instrument of drug abuse control, TIP*

- No. 5, p. 1-4, http://www.unodc.org/pdf/Alternative%20Development/AD_DrugControlInstrument.pdf
- 83 United Nations Office on Drugs and Crime (June 2015), 'Chapter 2, Alternative Development' & 'Annex I. Evolution of the Drug Control Treaties', *World Drug Report 2015*, http://www.unodc.org/wdr2015/field/WDR15_Chapter_2_Annex.pdf
- 84 Article 14, §3(a); see also: United Nations Office on Drugs and Crime (June 2015), 'Chapter 2, Alternative Development' & 'Annex I. Evolution of the Drug Control Treaties', *World Drug Report 2015*, http://www.unodc.org/wdr2015/field/WDR15_Chapter_2_Annex.pdf
- 85 General Assembly, forty-fourth session, Address by Mr. Virgilio Barco Vargas, President of the Republic of Colombia, Friday 29 September 1989, 3.45 p.m., A/44/PV.13, <http://www.mofa.gov.sd/pdf/44th%20Session%201989%20Mr%20Sahloul.pdf>
- 86 General Assembly (1993), *Measures to strengthen international cooperation against the illicit production, sale, demand, traffic and distribution of narcotic drugs and psychotropic substances and related activities*, A/RES/48/12, Para 10b, <http://www.un.org/documents/ga/res/48/a48r012.htm>
- 87 General Assembly (8 September 1998), *Resolution S-20/4. Measures to enhance international cooperation to counter the world drug problem – Action Plan on international cooperation on the eradication of illicit drug crops and on alternative development*, A/RES/S-20/4, <https://www.unodc.org/documents/alternative-development/UNGASSActionPlanAD.pdf>
- 88 Commission on Narcotic Drugs (2002), *Resolution 45/14. The role of alternative development in drug control and development cooperation*, E/CN.7/2002/11, https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2000-2009/2002/CND_Res-45-14.pdf
- 89 United Nations Office on Drugs and Crime (2005), *Alternative development: A global thematic evaluation*, p. 16, https://www.unodc.org/pdf/Alternative_Development_Evaluation_Dec-05.pdf
- 90 General Assembly (February 2014), *Resolution 68/196. United Nations guiding principles on alternative development*, A/RES/68/196, https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2010-2019/2013/A_RES_68_196.pdf. Unfortunately, UN entities specialised in development like UNDP and the FAO were not involved in the process
- 91 Ibid
- 92 The 7th thematic area of the 2016 UNGASS Outcome Document is titled: 'Operational recommendations on alternative development; regional, interregional and international cooperation on development-oriented balanced drug control policy; addressing socioeconomic issues'
- 93 International Harm Reduction Association (2010), *Through a harm reduction lens: Civil society engagement in multilateral decision making*, <https://www.hri.global/files/2010/06/01/CSEReportWeb.pdf>
- 94 United Nations, *General Assembly twentieth special session, 1st plenary meeting, Monday 8 June 1998*, A/S-20/PV.1, p. 3, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.1&Lang=E
- 95 Fordham, A. & Haase, H. 'Chapter 1: The 2016 UNGASS on drugs: A catalyst for the drug policy reform movement'. In: Klein, A. & Stothard, B. (2018), *Collapse of the global order on drugs* (Emerald Insight), <https://www.emeraldinsight.com/doi/pdfplus/10.1108/9781787564879>
- 96 See: <https://vngoc.org/beyond-2008/beyond-2008-forum/>
- 97 International Drug Policy Consortium (April 2009), *IDPC report of proceedings: The 2009 Commission on Narcotic Drugs and High Level Segment*, <http://idpc.net/publications/2009/04/idpc-proceedings-document-on-2009-cnd-high-level-segment>
- 98 See: CND Blog (12 March 2014), *3rd informal Civil Society Hearing, Opening session*, <http://cndblog.org/2014/03/3rd-informal-civil-society-hearing-opening-session/>
- 99 See: <https://www.cstfondrugs.org/>
- 100 President of the General Assembly (10 February 2016), *Summary of the President of the General Assembly on the Informal Interactive Stakeholder Consultation in support of the preparatory process for the United Nations General Assembly Special Session on the world drug problem (UNGASS)*, <http://fileservr.idpc.net/library/President-of-the-General-Assembly-Summary-of-February-10-Stakeholder-Consultation.pdf>
- 101 Commission on Narcotic Drugs (2018), *Resolution 61/10. Preparations for the ministerial segment to be held during the sixty-second session of the Commission on Narcotic Drugs, in 2019*, https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_61/CND_res2018/CND_Resolution_61_10.pdf
- 102 Commission on Narcotic Drugs (2019), *Conference room paper submitted by Switzerland on the views of civil society for drug policies beyond 2019*, https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_62/ECN72019_CRP7_V1901414.pdf
- 103 1988 United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, https://www.unodc.org/pdf/convention_1988_en.pdf
- 104 Jelsma, M. (2015), *UNGASS 2016: Prospects for treaty reform and UN system – Wide coherence on drug policy* (Brooking), https://www.tni.org/files/download/treaty_reform_drug_policy_ungass2016.pdf
- 105 United Nations, *General Assembly twentieth special session, 2nd plenary meeting, Monday 8 June 1998*, A/S-20/PV.2, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.2&Lang=E
- 106 United Nations, *General Assembly twentieth special session, 9th plenary meeting, Wednesday 10 June 1998*, A/S-20/PV.9, http://www.un.org/en/ga/search/view_doc.asp?symbol=A/S-20/PV.9&Lang=E

- 107 Blickman, T. (April 2002), *European cannabis policies under attack* (Transnational Institute), <http://www.undrugcontrol.info/en/issues/cannabis/item/2400-european-cannabis-policies-under-attack>; Bewley-Taylor, D., Jelsma, M. & Blickman, T. (March 2014), *The rise and decline of cannabis prohibition* (Transnational Institute & Global Drug Policy Observatory), <https://www.tni.org/en/publication/the-rise-and-decline-of-cannabis-prohibition>
- 108 Commission on Narcotic Drugs (2003), *Report of the forty-sixth session (15 March 2002 and 8-17 April 2003)*, E/CN.7/2003/19, para 75, https://www.unodc.org/unodc/en/commissions/CND/session/46_Session_2003/CND_46_Session.html
- 109 Bewley-Taylor, D. & Jelsma, M. (March 2012), *The limits of latitude – The UN drug control conventions*, Series on legislative reform of drug policies Nr. 18 (Transnational Institute & International Drug Policy Consortium), <https://www.tni.org/en/briefing/limits-latitude>
- 110 Costa, A.M. (May 2008), “*Making drug control ‘fit for purpose’: Building on the UNGASS decade*” - Report by the Executive Director of the United Nations Office on Drugs and Crime as a contribution to the review of the twentieth special session of the General Assembly, E/CN.7/2008/CRP.17*, https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_51/1_CRPs/E-CN7-2008-CRP17_E.pdf
- 111 William Brownfield, US Department of State (9 October 2014), *Trends in global drug policy*, <https://www.hsdl.org/?view&did=758628>
- 112 For a more detailed analysis, see: Lines, R., Barrett, D. & Gallahue, P. (December 2014), ‘Has the US just called for unilateral interpretation of multilateral obligations?’ *Opinio Juris*, <http://opiniojuris.org/2014/12/18/guest-post-us-just-called-unilateral-interpretation-multilateral-obligations/>
- 113 Bewley-Taylor, D. & Jelsma, M. (March 2012), *The limits of latitude – The UN drug control conventions*, Series on legislative reform of drug policies Nr. 18 (Transnational Institute & International Drug Policy Consortium), <https://www.tni.org/en/briefing/limits-latitude>
- 114 International Narcotics Control Board (19 April 2016), *Statement by Mr. Werner Sipp, President, International Narcotics Control Board (INCB), Special session of the General Assembly on the world drug problem*, http://www.incb.org/documents/Speeches/Speeches2016/INCB_speech_UNGASS_plenary_opening.pdf
- 115 Ibid. See also: United Nations Information Service (2 February 2015), *INCB warns against weakening the international drug control legal framework*, UNIS/NAR/1228, https://www.incb.org/documents/Publications/PressRelease/PR2015/press_release_020215.pdf
- 116 Blickman, T. (January 2013), *Objections to Bolivia’s reservation to allow coca chewing in the UN conventions* (Transnational Institute), <https://www.tni.org/en/article/objections-bolivas-reservation-allow-coca-chewing-un-conventions>
- 117 See Box 2 in: International Drug Policy Consortium (September 2016), *The UNGASS on the world drug problem: Report of proceedings*, <http://idpc.net/publications/2016/09/the-ungass-on-the-world-drug-problem-report-of-proceedings>
- 118 https://www.unodc.org/documents/commissions/CND/Drug_Resolutions/2010-2019/2014/CND_Res_57_10.pdf
- 119 World Health Organisation (2012), *WHO Expert Committee on Drug Dependence- Thirty-fifth Report*. WHO Technical Report Series 973, http://www.who.int/medicines/areas/quality_safety/35thecddmeet/en/
- 120 International Drug Policy Consortium (2015), *The 2015 Commission on Narcotic Drugs and its Special Session on Preparations for the United Nations General Assembly Special Session on the World Drug Problem – Report of Proceedings*, <http://idpc.net/publications/2015/06/the-2015-commission-on-narcotic-drugs-and-its-special-session-on-preparations-for-the-ungass-on-the-world-drug-problem-report-of-proceedings>
- 121 International Narcotics Control Board (2015), *Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. Indispensable, adequately available and not unduly restricted*, E/INCB/2015/1/Supp.1, http://www.incb.org/documents/Publications/AnnualReports/AR2015/English/Supplement-AR15_availability_English.pdf
- 122 19th WHO Model list of essential medicines (April 2015), www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf
- 123 Jelsma, M. (2016), *UNGASS 2016: Prospects for treaty reform and UN system-wide coherence on drug policy* (Transnational Institute), https://www.tni.org/files/download/treaty_reform_drug_policy_ungass2016.pdf
- 124 United Nations Chief Executives Board (November 2018), *United Nations system common position supporting the implementation of the international drug control policy through effective inter-agency collaboration*, CEB/2018/2, http://filesserver.idpc.net/library/CEB-2018-2-SoD_Common-position.pdf
- 125 General Assembly (December 1989), *Resolution 44/141. Global programme of action against illicit narcotic drugs*, A/RES/44/141, <http://www.un.org/documents/ga/res/44/a44r141.htm>
- 126 Jelsma, M. (December 2019), *UN Common Position on drug policy – Consolidating system-wide coherence* (International Drug Policy Consortium & Transnational Institute), <http://filesserver.idpc.net/library/UN-Common-Position-Briefing-Paper.pdf>
- 127 http://www.unmillenniumproject.org/resources/qa1_e.htm
- 128 United Nations Office on Drugs and Crime (February 2011), *Member States express strong support for “One-UN” approach of UNODC and other partners to transnational organized crime and drug trafficking*, <https://www.unodc.org/unodc/en/frontpage/2012/February/member-states->

[express-strong-support-for-one-un-approach-by-unodc-and-other-partners-on-transnational-organized-crime-and-drug-trafficking.html](#)

129 Hallam, C. (March 2016), *Striving for system-wide coherence: An analysis of the official contributions of United Nations entities for the UNGASS on drugs* (International Drug Policy Consortium), <http://idpc.net/publications/2016/03/striving-for-system-wide-coherence-an-analysis-of-the-official-contributions-of-united-nations-entities-for-the-ungass-on-drugs>

130 UN Women (2014), *A gender perspective on the impact of drug use, the drug trade, and drug control regimes*, http://www.unodc.org/documents/ungass2016//Contributions/UN/Gender_and_Drugs_-_UN_Women_Policy_Brief.pdf

131 See: http://www.unodc.org/ungass2016/en/contribution_UN_Entities.html

132 Hallam, C. (March 2016), *Striving for system-wide coherence: An analysis of the official contributions of United Nations entities for the UNGASS on drugs* (International Drug Policy Consortium), <http://idpc.net/publications/2016/03/striving-for-system-wide-coherence-an-analysis-of-the-official-contributions-of-united-nations-entities-for-the-ungass-on-drugs>

133 <http://www.undp.org/content/undp/en/home/sustainable-development-goals/goal-17-partnerships-for-the-goals.html>

134 Statement by Dr. Margaret Chan, former Director General of the World Health Organisation, available here: <http://cndblog.org/2017/03/cnd-plenary-agenda-item-2-adoption-of-the-agenda-and-other-organizational-matters/>

135 http://www.who.int/entity/substance_abuse/activities/msb_who_unodc_mou.pdf?ua=1

136 Jelsma, M. (December 2019), *UN Common Position on drug policy – Consolidating system-wide coherence* (International Drug Policy Consortium & Transnational Institute), <http://filesserver.idpc.net/library/UN-Common-Position-Briefing-Paper.pdf>

137 UN system coordination Task Team on the

Implementation of the UN System Common Position on drug-related matters (March 2019), *What we have learned over the last ten years: A summary of knowledge acquired and produced by the UN system on drug-related matters*, https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_62/ECN72019_CRP10_V1901490.pdf

138 Jelsma, M. (2003), 'Drugs in the UN system: The unwritten history of the 1998 United Nations General Assembly Special Session on drugs', *International Journal of Drug Policy*, **14**(2): 181-195

139 See, for example: The Guardian (30 November 2013), *Leaked paper reveals UN split over war on drugs*, <https://www.theguardian.com/politics/2013/nov/30/un-drugs-policy-split-leaked-paper>

140 See, for instance: Nougier, M., Cots Fernandez, A. & Putri, D. (April 2021), *Taking stock of half a decade of drug policy: An evaluation of UNGASS implementation* (International Drug Policy Consortium)

141 Csete, J. & Wolfe, D. (March 2017), 'Seeing through the public health smoke-screen in drug policy', *International Journal of Drug Policy*, **43**: 91-95, [http://www.ijdp.org/article/S0955-3959\(17\)30064-6/fulltext](http://www.ijdp.org/article/S0955-3959(17)30064-6/fulltext)

142 See: International Drug Policy Consortium (July 2020), *The 2020 Commission on Narcotic Drugs: Report of proceedings*, <https://idpc.net/publications/2020/07/the-2020-commission-on-narcotic-drugs-report-of-proceedings>; International Drug Policy Consortium (June 2019), *The 2019 Commission on Narcotic Drugs and its Ministerial Segment: Report of proceedings*, <https://idpc.net/publications/2019/06/the-2019-commission-on-narcotic-drugs-and-its-ministerial-segment-report-of-proceedings>; International Drug Policy Consortium (June 2018), *The 2018 Commission on Narcotic Drugs: Report of proceedings*, <https://idpc.net/publications/2018/06/the-2018-commission-on-narcotic-drugs-report-of-proceedings>; International Drug Policy Consortium (July 2017), *The 2017 Commission on Narcotic Drugs: Report of proceedings*, <http://idpc.net/publications/2017/07/the-2017-commission-on-narcotic-drugs-report-of-proceedings-july-2017>

About this Briefing Paper

In an effort to help digest and contextualise the UNGASS Outcome Document, this IDPC briefing paper explores a selection of key themes by analysing the consensus-based language agreed by UN member states during high-level meetings over the last quarter of a century. The briefing studies the evolution in agreed language on: the success/failure of drug control, harm reduction, human rights, development, civil society engagement, criminal justice responses and flexibilities in the conventions, access to controlled medicines and UN system-wide coherence.

International Drug Policy Consortium

Fifth Floor, 124-128 City Road
London EC1V 2NJ, United Kingdom

Tel: +44 (0)20 7324 2974

Email: contact@idpc.net

Website: www.idpc.net

About IDPC

The International Drug Policy Consortium (IDPC) is a global network of NGOs that come together to drug policies that advance social justice and human rights. IDPC's mission is to amplify and strengthen a diverse global movement to repair the harms caused by punitive drug policies, and to promote just responses.

© International Drug Policy Consortium Publication 2021

Report design by Mathew Birch - mathew@mathewbirch.com

Funded, in part, by:



OPEN SOCIETY
FOUNDATIONS